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RECOMMENDATION:
There is insufficient evidence to recommend bilateral DBS in 1 target over the other in order to minimize the risk of surgical adverse events.
The full guideline can be found at: https://www.cns.org/guidelines/deep-brainstimulation-parkinsons-disease. [1] [2] [3] [4] [5] [6] [7] However, the effectiveness of selecting different stimulation targets is less clear. To date, 2 different targets have been proposed for the treatment of motor symptoms of PD, the subthalamic nucleus (STN) and globus pallidus internus (GPi). While there is evidence to suggest that both are effective when combined with best medical treatment vs best medical treatment alone, 6 the circumstances in which 1 target should be selected over the other are still disputed. It is also unknown whether STN and GPi DBS induce similar benefits.
METHODS
Details of the systematic literature review are provided in the full text of this guideline (https://www.cns.org/guidelines/deep-brainstimulation-parkinsons-disease). A PubMed search was conducted for articles published between 1966 and February, 2017. Two different search strategies were used and the results were combined, yielding 151 unique abstracts. The selected studies were classified according to criteria for evidence on therapeutic effectiveness as detailed in the Joint Guidelines Committee Guideline Development Methodology.
RESULTS
The combined search queries yielded a total of 151 unique abstracts, which were screened for eligibility. A total of 18 articles were included in the final analysis. For Question 1, 2 Class I, 8, 9 2 Class II, 10,11 and 6 Class III 12-17 studies found no differences between the 2 targets in motor score improvements at various time points, up to 5 yr postoperatively, in various medication and stimulation conditions. In contrast, 2 articles, 18 1 Class I study, 18 found that STN stimulation is associated with greater improvement in motor scores assessed in the "off " medication/"on" stimulation condition. The advantage seen in the STN cohort in this study persisted at 3-yr follow-up. 11 No study to date has demonstrated a difference in the motor response to STN or GPi DBS in the "on" medication/"on" stimulation state.
With respect to Question 2, compelling evidence was derived from 3 Class I studies, 8, 9, 18 2 Class II studies, 11, 20 and 6 Class III studies 10, [12] [13] [14] [15] 17 showing greater reduction in dopaminergic medications following STN than GPi DBS. For the third question, a single study provides Class I evidence 18 that the severity of "on" medication dyskinesias, but not the amount of time with dyskinesias, is reduced to a greater extent following pallidal stimulation than subthalamic stimulation. The remaining 2 Class I studies showed no significant differences in the reduction of dyskinesias between these surgical targets. 8, 9 For Question 4, no study demonstrated a significant difference between the 2 targets regarding improvement in quality of life. Class I evidence from 3 studies have shown comparable improvements in quality of life as measured by the Unified Parkinson's Disease Rating Scale, Part II (UPDRS-II) at 1 yr, 8 the composite Parkinson's Disease Questionnaire (PDQ-39) at 2 yr, 9 or a quality of life questionnaire at 1 yr. 18 Three-year follow-up in the veterans affairs (VA) study utilized the PDQ-39 and did not reveal a difference between the 2 surgical targets, as shown by a single Class II study. 20 Six Class III studies 10, 12, 14, 15, 21, 22 showed improvements in quality of life following DBS without differences between the 2 targets. With respect to Question 5, neurocognitive function was formally assessed using various batteries in 5 studies. 9, 18, 20, 23, 24 Class I evidence was provided by 3 of these studies, in which patients and assessors were blinded to the stimulation site. 9, 18, 23 In 1 of these studies, 9 STN DBS was associated with a significantly greater decline in processing speed and working memory compared to GPi DBS.
For Question 6, Class I evidence from the VA Cooperative Study demonstrated a slight improvement in the GPi group (5.8%) compared to a slight worsening in the STN group (-11.6%) on the Beck Depression Inventory (BDI; P = .02). 9 There were no differences between groups when this cohort was assessed for suicidal ideation and suicidal behaviors at 6, 12, and 24 mo postoperatively using the UPDRS-I. 25 The NSTAPS 3-yr follow-up study found that there were no differences between targets when measuring with a composite of mood, cognitive, and behavioral effects (Class II). 11 Class III evidence comes from 2 trials. A retrospective study of 27 patients demonstrated that both GPi and STN DBS groups were associated with a trend towards reduced Hamilton Depression Scale scores up to 12 mo postoperatively. 17 Another retrospective series demonstrated decreases on the BDI score 12 mo postoperatively in both the STN DBS group (21.1%) and the GPi group (27.0%). 24 Thus, there is Class I evidence from a single study suggesting that, compared to STN DBS, GPi stimulation is associated with better outcomes in terms of depression. For Question 7, no study showed a significantly higher risk of adverse events related to 1 surgical target over another.
DISCUSSION AND CONCLUSION
PD is characterized by many symptoms, which may vary in severity and response to medications and DBS. This clinical heterogeneity can make selection of the appropriate target for DBS somewhat complex. Based on the current literature, there are areas of agreement and disagreement over the question of target superiority in DBS for the treatment of PD. Ultimately, the selection of a specific brain target for stimulation should be tailored to the needs of the individual patient.
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